ESMO 2023 | 7-year results from CheckMate 238: adjuvant nivolumab in melanoma

Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy, discusses 7 year follow-up findings from the Phase III CheckMate 238 (NCT02388906) of adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma. Relapse-free survival and disease-free survival were superior in the nivolumab arm. Despite overall survival being similar in both arms, time to second objective disease progression (PFS2) was higher in patients receiving nivolumab. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.